Summary
Ligand Pharmaceuticals, Inc. (Ligand), formerly Progenx Inc., is a biopharmaceutical company develops and acquires technologies that help in discovery and development of medicines. The company offers a diversified portfolio of biotechnology and pharmaceutical products. Its marketed product portfolio encompasses indication for fungal infections, arrhythmia, hepatitis C, menopause, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand’s clinical development portfolio comprises medications targeted at the treatment of seizure, cancer, diabetes, coma, cardiovascular disease, liver disease, muscle wasting, kidney disease, and others. The company’s service offerings include early-stage drug development, drug discovery, product reformulation. In partnership with other pharmaceutical companies the company also offers late-stage development, regulatory management and commercialization support. Ligand is headquartered in San Diego, California, the US.
Ligand Pharmaceuticals, Inc. (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 17
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 18
Ligand Pharma Acquires Milestones And Royalty Interests For MEDI-528 From Genaera Liquidating 20
Genaera Sells IL-9 To Ligand Pharma And Biotech Value Fund 21
Partnerships 22
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 22
Symphogen Enters Into Agreement With Open Monoclonal Technology 23
Open Monoclonal Expands Agreement with CNA Development 24
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 26
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 27
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 31
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32
CyDex Pharma Terminates Co-Development Agreement With Prism Pharma 33
GlaxoSmithKline Terminates Co-Development Agreement With Pharmacopeia 34
Licensing Agreements 35
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 35
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 36
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 37
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 38
RODES Enters into Licensing Agreement with Ligand Pharma 39
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 40
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 41
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 42
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 43
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Sanofi Enters into Licensing Agreement with Ligand Pharma 45
Open Monoclonal Enters into Licensing Agreement with Amgen 46
Ligand Pharma Enters into Licensing Agreement with Sermonix Pharma for Lasofoxifene 47
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 48
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 49
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 50
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 51
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 52
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 57
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 59
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 60
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 61
Ligand Pharma Enters Into Licencing Agreement With Merck 63
Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 64
Ligand Pharma Enters Into Licensing Agreement With Hospira 66
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 67
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 68
Merck Terminates Licensing Agreement With Ligand Pharma 70
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 71
Ligand Pharma Terminates Licensing Agreement With MedImmune 73
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 74
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 76
Ligand Pharma Enters Into Sublicensing Agreement With Pfizer 78
Rib-X Pharma Enters into Licensing and Supply Agreement with Ligand Pharma 80
Ligand Pharma Terminates Its Collaboration And Licensing Agreement With F. Hoffmann-La Roche 81
Ligand Pharma Enters Into Licensing Agreement With Proximagen Group 82
CyDex Pharma Enters Into Licensing Agreement With University Of Kansas 83
Equity Offering 84
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 84
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 85
Debt Offering 87
Ligand Pharma Prices Private Placement of 0.75% Notes Due 2019 for USD225 Million 87
Asset Transactions 89
Ligand Pharma Completes Sale Of Its Combinatorial Chemical Library To Venenum Biodesign 89
Acquisition 90
Ligand Pharma to Acquire Open Monoclonal Technology for USD178 Million 90
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 91
Ligand Pharma Acquires CyDex Pharma 92
Ligand Pharma Acquires Metabasis Therapeutics 94
Ligand Pharmaceuticals, Inc. - Key Competitors 96
Key Employees 97
Locations And Subsidiaries 98
Head Office 98
Other Locations & Subsidiaries 98
Appendix 100
Methodology 100
About GlobalData 100
Contact Us 100
Disclaimer 100
List of Tables
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Ligand Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 10
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 17
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 18
Ligand Pharma Acquires Milestones And Royalty Interests For MEDI-528 From Genaera Liquidating 20
Genaera Sells IL-9 To Ligand Pharma And Biotech Value Fund 21
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 22
Symphogen Enters Into Agreement With Open Monoclonal Technology 23
Open Monoclonal Expands Agreement with CNA Development 24
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 26
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 27
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 31
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32
CyDex Pharma Terminates Co-Development Agreement With Prism Pharma 33
GlaxoSmithKline Terminates Co-Development Agreement With Pharmacopeia 34
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 35
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 36
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 37
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 38
RODES Enters into Licensing Agreement with Ligand Pharma 39
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 40
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 41
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 42
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 43
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Sanofi Enters into Licensing Agreement with Ligand Pharma 45
Open Monoclonal Enters into Licensing Agreement with Amgen 46
Ligand Pharma Enters into Licensing Agreement with Sermonix Pharma for Lasofoxifene 47
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 48
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 49
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 50
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 51
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 52
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 57
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 59
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 60
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 61
Ligand Pharma Enters Into Licencing Agreement With Merck 63
Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 64
Ligand Pharma Enters Into Licensing Agreement With Hospira 66
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 67
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 68
Merck Terminates Licensing Agreement With Ligand Pharma 70
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 71
Ligand Pharma Terminates Licensing Agreement With MedImmune 73
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 74
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 76
Ligand Pharma Enters Into Sublicensing Agreement With Pfizer 78
Rib-X Pharma Enters into Licensing and Supply Agreement with Ligand Pharma 80
Ligand Pharma Terminates Its Collaboration And Licensing Agreement With F. Hoffmann-La Roche 81
Ligand Pharma Enters Into Licensing Agreement With Proximagen Group 82
CyDex Pharma Enters Into Licensing Agreement With University Of Kansas 83
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 84
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 85
Ligand Pharma Prices Private Placement of 0.75% Notes Due 2019 for USD225 Million 87
Ligand Pharma Completes Sale Of Its Combinatorial Chemical Library To Venenum Biodesign 89
Ligand Pharma to Acquire Open Monoclonal Technology for USD178 Million 90
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 91
Ligand Pharma Acquires CyDex Pharma 92
Ligand Pharma Acquires Metabasis Therapeutics 94
Ligand Pharmaceuticals, Inc., Key Competitors 96
Ligand Pharmaceuticals, Inc., Key Employees 97
Ligand Pharmaceuticals, Inc., Subsidiaries 98
List of Figures
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
